DOCSLIB.ORG

Table S1 List of Genes/Proteins Shared Between NAFLD, Fibrosis, and Inflammation Gene Symbol Description Gene ID

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table S1 List of Genes/Proteins Shared Between NAFLD, Fibrosis, and Inflammation Gene Symbol Description Gene ID Table S1 List of genes/proteins shared between NAFLD, fibrosis, and inflammation Gene symbol Description Gene ID ANGPTL2 ANGPTL2 (angiopoietin like 2) 23452 ESM1 ESM1 (endothelial cell specific molecule 1) 11082 CXCL16 CXCL16 (C-X-C motif chemokine ligand 16) 58191 DUSP1 DUSP1 (dual specificity phosphatase 1) 1843 CD163 CD163 (CD163 molecule) 9332 TNFRSF6B TNFRSF6B (TNF receptor superfamily member 6b) 8771 NR1H2 NR1H2 (nuclear receptor subfamily 1 group H member 2) 7376 PLA2G2A PLA2G2A (phospholipase A2 group IIA) 5320 NOX4 NOX4 (NADPH oxidase 4) 50507 DDIT3 DDIT3 (DNA damage inducible transcript 3) 1649 CXCR3 CXCR3 (C-X-C motif chemokine receptor 3) 2833 IL6ST IL6ST (interleukin 6 signal transducer) 3572 OLR1 OLR1 (oxidized low-density lipoprotein receptor 1) 4973 CNR2 CNR2 (cannabinoid receptor 2) 1269 TFPI TFPI (tissue factor pathway inhibitor) 7035 P2RX7 P2RX7 (purinergic receptor P2X 7) 5027 WNT5A WNT5A (Wnt family member 5A) 7474 THBD THBD (thrombomodulin) 7056 HAMP HAMP (hepcidin antimicrobial peptide) 57817 CHI3L1 CHI3L1 (chitinase 3 like 1) 1116 SMAD7 SMAD7 (SMAD family member 7) 4092 PPARD PPARD (peroxisome proliferator activated receptor delta) 5467 CD36 CD36 (CD36 molecule) 948 TIMP1 TIMP1 (TIMP metallopeptidase inhibitor 1) 7076 PDCD1 PDCD1 (programmed cell death 1) 5133 MMP3 MMP3 (matrix metallopeptidase 3) 4314 TNF TNF (tumor necrosis factor) 7124 IL6 IL6 (interleukin 6) 3569 CXCL8 CXCL8 (C-X-C motif chemokine ligand 8) 3576 IL1B IL1B (interleukin 1 beta) 3553 IL17A IL17A (interleukin 17A) 3605 NFKB1 NFKB1 (nuclear factor kappa B subunit 1) 4790 HMGB1 HMGB1 (high mobility group box 1) 3146 TLR4 TLR4 (toll like receptor 4) 7099 IL10 IL10 (interleukin 10) 3586 TLR2 TLR2 (toll like receptor 2) 7097 MIF MIF (macrophage migration inhibitory factor) 4282 CCL2 CCL2 (C-C motif chemokine ligand 2) 6347 IL33 IL33 (interleukin 33) 90865 NLRP3 NLRP3 (NLR family pyrin domain containing 3) 114548 STAT3 STAT3 (signal transducer and activator of transcription 3) 6774 IFNG IFNG (interferon gamma) 3458 TGFB1 TGFB1 (transforming growth factor beta 1) 7040 IL18 IL18 (interleukin 18) 3606 NFE2L2 NFE2L2 (nuclear factor, erythroid 2 like 2) 4780 TNFSF12 TNFSF12 (TNF superfamily member 12) 8742 IL22 IL22 (interleukin 22) 50616 MAPK14 MAPK14 (mitogen-activated protein kinase 14) 1432 SOCS3 SOCS3 (suppressor of cytokine signaling 3) 9021 IL32 IL32 (interleukin 32) 9235 HMOX1 HMOX1 (heme oxygenase 1) 3162 PTGS2 PTGS2 (prostaglandin-endoperoxide synthase 2) 5743 IL4 IL4 (interleukin 4) 3565 CXCL10 CXCL10 (C-X-C motif chemokine ligand 10) 3627 IL23A IL23A (interleukin 23 subunit alpha) 51561 MAPK1 MAPK1 (mitogen-activated protein kinase 1) 5594 IL13 IL13 (interleukin 13) 3596 SOCS1 SOCS1 (suppressor of cytokine signaling 1) 8651 AGER AGER (advanced glycosylation end-product specific receptor) 177 CCL5 CCL5 (C-C motif chemokine ligand 5) 6352 TNFSF10 TNFSF10 (TNF superfamily member 10) 8743 IL1RN IL1RN (interleukin 1 receptor antagonist) 3557 MMP9 MMP9 (matrix metallopeptidase 9) 4318 VCAM1 VCAM1 (vascular cell adhesion molecule 1) 7412 VEGFA VEGFA (vascular endothelial growth factor A) 7422 ICAM1 ICAM1 (intercellular adhesion molecule 1) 3383 F3 F3 (coagulation factor III, tissue factor) 2152 TLR3 TLR3 (toll like receptor 3) 7098 PPARG PPARG (peroxisome proliferator activated receptor gamma) 5468 MAPK8 MAPK8 (mitogen-activated protein kinase 8) 5599 STAT1 STAT1 (signal transducer and activator of transcription 1) 6772 TNFRSF1A TNFRSF1A (TNF receptor superfamily member 1A) 7132 IL27 IL27 (interleukin 27) 246778 IL1RL1 IL1RL1 (interleukin 1 receptor like 1) 9173 NAMPT NAMPT (nicotinamide phosphoribosyltransferase) 10135 IL21 IL21 (interleukin 21) 59067 CRP CRP (C-reactive protein) 1401 LEP LEP (leptin) 3952 AKT1 AKT1 (AKT serine/threonine kinase 1) 207 NOS2 NOS2 (nitric oxide synthase 2) 4843 CTGF CTGF (connective tissue growth factor) 1490 TREM1 TREM1 (triggering receptor expressed on myeloid cells 1) 54210 CCL20 CCL20 (C-C motif chemokine ligand 20) 6364 CD40 CD40 (CD40 molecule) 958 RETN RETN (resistin) 56729 SIRT1 SIRT1 (sirtuin 1) 23411 SPP1 SPP1 (secreted phosphoprotein 1) 6696 NFKBIA NFKBIA (NFKB inhibitor alpha) 4792 IL2 IL2 (interleukin 2) 3558 TLR7 TLR7 (toll like receptor 7) 51284 GDF15 GDF15 (growth differentiation factor 15) 9518 SAA1 SAA1 (serum amyloid A1) 6288 HIF1A HIF1A (hypoxia inducible factor 1 subunit alpha) 3091 TNFAIP3 TNFAIP3 (TNF alpha induced protein 3) 7128 ADIPOQ ADIPOQ (adiponectin, C1Q and collagen domain containing) 9370 CX3CL1 CX3CL1 (C-X3-C motif chemokine ligand 1) 6376 TLR9 TLR9 (toll like receptor 9) 54106 S100A9 S100A9 (S100 calcium binding protein A9) 6280 JUN JUN (Jun proto-oncogene, AP-1 transcription factor subunit) 3725 PTX3 PTX3 (pentraxin 3) 5806 MMP1 MMP1 (matrix metallopeptidase 1) 4312 TNFSF13B TNFSF13B (TNF superfamily member 13b) 10673 NR1H3 NR1H3 (nuclear receptor subfamily 1 group H member 3) 10062 MMP2 MMP2 (matrix metallopeptidase 2) 4313 CD40LG CD40LG (CD40 ligand) 959 S100A8 S100A8 (S100 calcium binding protein A8) 6279 EGFR EGFR (epidermal growth factor receptor) 1956 SERPINE1 SERPINE1 (serpin family E member 1) 5054 TNFRSF1B TNFRSF1B (TNF receptor superfamily member 1B) 7133 CD14 CD14 (CD14 molecule) 929 CD274 CD274 (CD274 molecule) 29126 HGF HGF (hepatocyte growth factor) 3082 LCN2 LCN2 (lipocalin 2) 3934 PPARA PPARA (peroxisome proliferator activated receptor alpha) 5465 MTOR MTOR (mechanistic target of rapamycin kinase) 2475 FOXO3 FOXO3 (forkhead box O3) 2309 TNFSF11 TNFSF11 (TNF superfamily member 11) 8600 TNFRSF11B TNFRSF11B (TNF receptor superfamily member 11b) 4982 PIK3CA PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) 5290 EDN1 EDN1 (endothelin 1) 1906 GSK3B GSK3B (glycogen synthase kinase 3 beta) 2932 CXCL12 CXCL12 (C-X-C motif chemokine ligand 12) 6387 SMAD3 SMAD3 (SMAD family member 3) 4088 TP53 TP53 (tumor protein p53) 7157 CXCL9 CXCL9 (C-X-C motif chemokine ligand 9) 4283 FAS FAS (Fas cell surface death receptor) 355 LTA LTA (lymphotoxin alpha) 4049 CX3CR1 CX3CR1 (C-X3-C motif chemokine receptor 1) 1524 RARRES2 RARRES2 (retinoic acid receptor responder 2) 5919 FASLG FASLG (Fas ligand) 356 ENPP2 ENPP2 (ectonucleotide pyrophosphatase/phosphodiesterase 2) 5168 THBS1 THBS1 (thrombospondin 1) 7057 NGF NGF (nerve growth factor) 4803 IGF1R IGF1R (insulin like growth factor 1 receptor) 3480 LGALS3 LGALS3 (galectin 3) 3958 PGF PGF (placental growth factor) 5228 FOXP3 FOXP3 (forkhead box P3) 50943 TNFSF13 TNFSF13 (TNF superfamily member 13) 8741 MAPK9 MAPK9 (mitogen-activated protein kinase 9) 5601 TNFAIP8L2 TNFAIP8L2 (TNF alpha induced protein 8 like 2) 79626 ANGPT2 ANGPT2 (angiopoietin 2) 285 CXCL11 CXCL11 (C-X-C motif chemokine ligand 11) 6373 SIRT6 SIRT6 (sirtuin 6) 51548 CFH CFH (complement factor H) 3075 FABP4 FABP4 (fatty acid binding protein 4) 2167 CXCL13 CXCL13 (C-X-C motif chemokine ligand 13) 10563 ITGAV ITGAV (integrin subunit alpha V) 3685 DPP4 DPP4 (dipeptidyl peptidase 4) 1803 PRKAA1 PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) 5562 MET MET (MET proto-oncogene, receptor tyrosine kinase) 4233 ANGPT1 ANGPT1 (angiopoietin 1) 284 NR1H4 NR1H4 (nuclear receptor subfamily 1 group H member 4) 9971 BIRC5 BIRC5 (baculoviral IAP repeat containing 5) 332 GRN GRN (granulin precursor) 2896 ADM ADM (adrenomedullin) 133 PTEN PTEN (phosphatase and tensin homolog) 5728 NOS3 NOS3 (nitric oxide synthase 3) 4846 C3 C3 (complement C3) 718 EPO EPO (erythropoietin) 2056 BCL2 BCL2 (BCL2, apoptosis regulator) 596 YAP1 YAP1 (Yes associated protein 1) 10413 NOTCH1 NOTCH1 (notch 1) 4851 POSTN POSTN (periostin) 10631 LEPR LEPR (leptin receptor) 3953 HSPD1 HSPD1 (heat shock protein family D (Hsp60) member 1) 3329 BBC3 BBC3 (BCL2 binding component 3) 27113 APOA1 APOA1 (apolipoprotein A1) 335 CDKN1A CDKN1A (cyclin dependent kinase inhibitor 1A) 1026 HSPB1 HSPB1 (heat shock protein family B (small) member 1) 3315 MFGE8 MFGE8 (milk fat globule-EGF factor 8 protein) 4240 FLT1 FLT1 (fms related tyrosine kinase 1) 2321 KLF6 KLF6 (Kruppel like factor 6) 1316 GHRL GHRL (ghrelin and obestatin prepropeptide) 51738 CCR2 CCR2 (C-C motif chemokine receptor 2) 729230 CTNNB1 CTNNB1 (catenin beta 1) 1499 AGT AGT (angiotensinogen) 183 ATF4 ATF4 (activating transcription factor 4) 468 CCR5 CCR5 [C-C motif chemokine receptor 5 (gene/pseudogene)] 1234 INS INS (insulin) 3630 SOD2 SOD2 (superoxide dismutase 2) 6648 DLL4 DLL4 (delta like canonical Notch ligand 4) 54567 CNR1 CNR1 (cannabinoid receptor 1) 1268 MERTK MERTK (MER proto-oncogene, tyrosine kinase) 10461 HSPA5 HSPA5 [heat shock protein family A (Hsp70) member 5] 3309 IGF1 IGF1 (insulin like growth factor 1) 3479 MPO MPO (myeloperoxidase) 4353 SERPINF1 SERPINF1 (serpin family F member 1) 5176 CLU CLU (clusterin) 1191 CTF1 CTF1 (cardiotrophin 1) 1489 ADIPOR2 ADIPOR2 (adiponectin receptor 2) 79602 CD44 CD44 (CD44 molecule (Indian blood group)) 960 C5 C5 (complement C5) 727 CEBPA CEBPA (CCAAT enhancer binding protein alpha) 1050 NR1I2 NR1I2 (nuclear receptor subfamily 1 group I member 2) 8856 SERPINA1 SERPINA1 (serpin family A member 1) 5265 TRIB3 TRIB3 (tribbles pseudokinase 3) 57761 ANXA2 ANXA2 (annexin A2) 302 GREM1 GREM1 (gremlin 1, DAN family BMP antagonist) 26585 ABCA1 ABCA1 (ATP binding cassette subfamily A member 1) 19 CYP7A1 CYP7A1 (cytochrome P450 family 7 subfamily A member 1) 1581 IGFBP1 IGFBP1 (insulin like growth factor binding protein 1) 3484 NGFR NGFR (nerve growth factor receptor) 4804 KDR KDR (kinase insert domain receptor) 3791 TIMP2 TIMP2 (TIMP metallopeptidase inhibitor 2) 7077 AOC3 AOC3
Load more

Recommended publications
  • Polymorphisms with Late-Onset Alzheimer Disease in Han Chinese
    172 Original Article on Translational Neurodegeneration Page 1 of 8 Association of lectin-like oxidized low density lipoprotein receptor 1 (OLR1) polymorphisms with late-onset Alzheimer disease in Han Chinese Zuo-Teng Wang1#, Xiao-Ling Zhong2#, Meng-Shan Tan1, Hui-Fu Wang1, Chen-Chen Tan1, Wei Zhang1, Zhan-Jie Zheng3, Ling-Li Kong3, Lan Tan1, Li Sun2 1Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao 266071, China; 2Department of Neurology, Qingdao Central Hospital, Qingdao University, Qingdao 266042, China; 3Department of Geriatric, Qingdao Mental Health Center, Qingdao 266034, China Contributions: (I) Conception and design: All authors; (II) Administrative support: All authors; (III) Provision of study materials or patients: All authors; (VI) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors should be regarded as co-first authors. Correspondence to: Dr. Lan Tan, MD, PhD. Department of Neurology, Qingdao Municipal Hospital, Qingdao University, No. 5 Donghai Middle Road, Qingdao 266071, China. Email: [email protected]; Dr. Li Sun, MD, PhD. Department of Neurology, Qingdao Central Hospital, Qingdao University, Qingdao 266042, China. Email: [email protected]. Background: Lectin-like oxidized low density lipoprotein receptor 1 (OLR1) locates within the area of chromosome 12p, which has been identified as the AD-susceptible region, and plays a role in lipid metabolism. Therefore, it has been suggested to be a good candidate gene for Alzheimer’s disease (AD). Several SNPs within OLR1 have been reported to have association with AD among Caucasians. Methods: We selected and genotyped three SNPs (rs1050283, rs1050286, rs17808009) in OLR1 to investigate its possible relationship with the onset of late-onset Alzheimer disease(LOAD) in 984 LOAD cases and 1,354 healthy controls among northern Han Chinese.
    [Show full text]
  • Genome Wide Analysis of TLR1/2- and TLR4-Activated SZ95 Sebocytes
    RESEARCH ARTICLE Genome wide analysis of TLR1/2- and TLR4- activated SZ95 sebocytes reveals a complex immune-competence and identifies serum amyloid A as a marker for activated sebaceous glands DaÂniel ToÈ rőcsik1,2*, DoÂra KovaÂcs1, SzilaÂrd PoÂliska3, Zita Szentkereszty-KovaÂcs1, a1111111111 Marianna LovaÂszi1, Katalin Hegyi1, Andrea Szegedi1,4, Christos C. Zouboulis5, a1111111111 Mona Ståhle2 a1111111111 a1111111111 1 Department of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, 2 Unit of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, a1111111111 Stockholm, Sweden, 3 Department of Biochemistry and Molecular Biology, Genomic Medicine and Bioinformatics Core Facility, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, 4 Division of Dermatological Allergology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, 5 Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodore Fontane, Dessau, Germany OPEN ACCESS * [email protected] Citation: ToÈrőcsik D, KovaÂcs D, PoÂliska S, Szentkereszty-KovaÂcs Z, LovaÂszi M, Hegyi K, et al. (2018) Genome wide analysis of TLR1/2- and TLR4-activated SZ95 sebocytes reveals a complex Abstract immune-competence and identifies serum amyloid A as a marker for activated sebaceous glands. Toll-like receptors (TLR) 2 and 4 are active in sebaceous glands and play a central role in PLoS ONE 13(6): e0198323. https://doi.org/ the development of acne. Still, there is only limited knowledge on their effect on sebocytes. 10.1371/journal.pone.0198323 In this work we performed global gene expression profile analysis with functional clustering Editor: Mauro Picardo, San Gallicano Dermatologic of the differentially regulated genes of TLR1/2 (PAM3CSK4)- and TLR4 (lipopolysaccharide Institute, ITALY [LPS])-activated SZ95 sebocytes.
    [Show full text]
  • Basic Science * Drug X Is Used for Ongoing IP/Patent Assessment Heart: First Published As 10.1136/Heartjnl-2021-BCS.199 on 4 June 2021
    Abstracts Basic science * Drug X is used for ongoing IP/patent assessment Heart: first published as 10.1136/heartjnl-2021-BCS.199 on 4 June 2021. Downloaded from Conflict of Interest No BS1 REPROGRAMMING HUMAN MACROPHAGES WITH DRUG X: POTENTIAL MECHANISMS FOR STABILISATION OF ATHEROSCLEROTIC PLAQUES BS2 MECHANOSENSOR PIEZO1 IN SKELETAL MUSCLE PERICYTES 1Klaudia Kocsy, 1Endre Kiss-Toth, 2Jessica Redgrave, 2Arshad Majid, 3Sheila Francis. 1Department of Infection, Immunity & Cardiovascular Disease, The University of Sheffield, 1Yilizila Abudushalamu, 1Hema Viswambharan, 2Romana Mughal, 1Richard Cubbon, Sheffield, UK; 2Department of Neuroscience, The University of Sheffield, Sheffield, UK; 3The 1Mark Kearney, 1David Beech, 1Piruthivi Sukumar. 1Discovery and Translational Science University of Sheffield, Sheffield, UK Department Leeds Institute of Cardiovascular and Metabolic Medic, Leeds, UK; 2Department of Optometry and Vision Sciences School of Applied Sciences University of Huddersfield 10.1136/heartjnl-2021-BCS.199 10.1136/heartjnl-2021-BCS.200 Introduction Ischemic stroke is commonly caused by large artery atherosclerosis. Patients with a high atherosclerotic bur- Introduction Pericytes (PC) are mural cells which are present den (stenosis) and inflamed or ulcerated plaque are at in blood microvessels. They play an important part in the for- increased risk of early recurrent ischaemic events. Treatment mation and stabilization of new blood vessels. They are essen- with anti-inflammatory agents may therefore reduce stroke tial for vascular development and cardiovascular homeostasis. incidence and recurrence in patients with this condition, but They wrap around the endothelial cells (EC) and endothelial- in vitro human studies of the possible mechanisms are lacking. pericyte communication is both via physical contact and para- 1 We hypothesised that an anti-inflammatory compound crine signalling.
    [Show full text]
  • MOUSE INTERLEUKIN-28B/INTERFERON-LAMBDA 3, CARRIER FREE Product Number: 12821-1 Lot Number: 5559 Size: 25 Μg
    MOUSE INTERLEUKIN-28B/INTERFERON-LAMBDA 3, CARRIER FREE Product Number: 12821-1 Lot Number: 5559 Size: 25 µg Description: Mouse Interleukin-28B/Interferon-lambda 3, Carrier Free Source: A DNA sequence encoding the mature mouse IL-28B/IFN-λ3 (Asp 20 - Val 193) (Kotenko, S.V. et al., 2003, Nat. Immunol. 4(1):69 - 77) was expressed in E. coli. Form: Lyophilized Buffer: Phosphate-buffered saline (PBS) Reconstitution: It is recommended that sterile PBS be added to the vial to prepare a stock solution of no less than 100 μg/mL. Endotoxin: < 1 EU/µg Molecular Weight: The 175 amino acid residue methionyl form of recombinant mouse IL-28B has a predicted molecular mass of approximately 19.7 kDa. Purity: > 95% Synonyms: Mu IL-28B; Mu IFN-λ3 Accession #: NP_796370 Assays Used to Measure Bioactivity: Human HepG2 cells infected with encephalomyocarditis virus (Sheppard, P. et al., 2003, Nature Immunol. 4:63). The ED50 for this effect is typically 7.5 - 37.5 ng/mL. Shipping Conditions: Wet Ice Physical State of Product During Shipping: Lyophilized Special Conditions/Comments: After receipt, this product should be kept at -70˚C or below for retention of full activity. Upon reconstitution, this cytokine can be stored under sterile conditions at 2˚C to 8˚C for one month or at -20˚C to -70˚C in a manual defrost freezer for three months without detection loss of activity. Avoid repeated freeze-thaw cycles. For more information on protein handling, visit the PBL website at www.interferonsource.com . Product Information: Human IL-28A, IL-28B, and IL-29, also named interferon-λ2 (IFN-λ2), IFN-λ3, and IFN-λ1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11- 13% aa sequence identity) and type I IFN family (15 - 19% aa sequence identity).1 – 3 The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons.
    [Show full text]
  • Molecular Characterization of Tea Catechin Treated Human Prostate Cancer Cell Lines Yewseok Suh
    Florida State University Libraries Electronic Theses, Treatises and Dissertations The Graduate School 2006 Molecular Characterization of Tea Catechin Treated Human Prostate Cancer Cell Lines Yewseok Suh Follow this and additional works at the FSU Digital Library. For more information, please contact [email protected] THE FLORIDA STATE UNIVERSITY COLLEGE OF ARTS AND SCIENCES MOLECULAR CHARACTERIZATION OF TEA CATECHIN TREATED HUMAN PROSTATE CANCER CELL LINES By YEWSEOK SUH A Dissertation submitted to the Department of Chemistry and Biochemistry in partial fulfillment of the requirements for the degree of Doctor of Philosophy Degree Awarded: Summer Semester, 2006 The members of the Committee approve the dissertation of Yewseok Suh defended on May 12, 2006. Qing-Xiang Amy Sang Professor Directing Dissertation Thomas C.S. Keller III Outside Committee Member Joseph B. Schlenoff Committee Member Hong Li Committee Member Approved: Naresh Dalal, Chair, Department of Chemistry and Biochemistry Joseph Travis, Dean, College of Arts and Sciences The Office of Graduate Studies has verified and approved the above named committee members. ii This dissertation is dedicated to my parents for their endless love and encouragement, to my lovely wife Inok Park for her support, and to our charming daughter, Tae-won. iii ACKNOWLEDGEMENTS I would like to express my gratitude to my major professor for her support throughout the research. Also thanks to all my committee members, Dr. Thomas C. S. Keller III, Dr. Hong Li, and Dr. Joseph B. Schlenoff, for their support, advice, and guidance. Special thanks to our lab members especially, Ziad Sahab and Robert G. Newcomer and former lab member Douglas R.
    [Show full text]
  • 2018 Chen Lingyan 1448129
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Genetics and Epigenetics in Systemic Lupus Erythematosus Chen, Lingyan Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 03. Oct. 2021 GENETICS AND EPIGENETICS IN SYSTEMIC LUPUS ERYTHEMATOSUS Lingyan CHEN Department of Medical & Molecular Genetics Faculty of Life Sciences & Medicine King’s College London This thesis is submitted for the degree of DoCtor of Philosophy (PhD) 1 To my parents 2 DeClaration The work described in this thesis was carried out within the Vyse Immunogenetics Group in the Department of Medical and Molecular Genetics at King’s College London under the supervision of Professor Timothy James Vyse and Dr David Lester Morris and between the years of October 2014 and March 2018.
    [Show full text]
  • Ncounter® Autoimmune Discovery Consortium Panel
    nCounter® Autoimmune Discovery Consortium Panel - Gene Details Official Symbol Accession Alias / Previous Symbol Official Full Name Other targets or Isoform Information AAMP NM_001087.3 angio associated migratory cell protein ABHD6 NM_020676.5 abhydrolase domain containing 6 ACKR2 NM_001296.3 CMKBR9,CCBP2;chemokine binding protein 2 atypical chemokine receptor 2 ACOXL NM_018308.1 acyl-Coenzyme A oxidase-like acyl-CoA oxidase like ACSL6 NM_001009185.1 FACL6;fatty-acid-Coenzyme A ligase, long-chain 6 acyl-CoA synthetase long chain family member 6 ADA NM_000022.2 adenosine deaminase ADAM30 NM_021794.2 a disintegrin and metalloproteinase domain 30 ADAM metallopeptidase domain 30 ADCY3 NM_004036.3 adenylate cyclase 3 ADCY7 NM_001114.4 adenylate cyclase 7 AFF3 NM_001025108.1 LAF4;lymphoid nuclear protein related to AF4,AF4/FMR2 family, member 3 AF4/FMR2 family member 3 AGAP2 NM_014770.3 CENTG1;centaurin, gamma 1 ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 AHI1 NM_001134830.1 Abelson helper integration site Abelson helper integration site 1 AHR NM_001621.3 aryl hydrocarbon receptor AHSA2;AHA1, activator of heat shock 90kDa protein ATPase homolog 2 AHSA2 NM_152392.1 (yeast),activator of HSP90 ATPase homolog 2 activator of HSP90 ATPase homolog 2, pseudogene APECED;autoimmune regulator (autoimmune polyendocrinopathy candidiasis AIRE NM_000383.2 ectodermal dystrophy) autoimmune regulator AMIGO3 NM_198722.2 adhesion molecule with Ig like domain 3 ANKRD55 NM_024669.2 ankyrin repeat domain 55 ANTXR2 NM_058172.5 anthrax toxin receptor
    [Show full text]
  • Evaluating the Effect of TLR4-Overexpressing on The
    Guo et al. J of Biol Res-Thessaloniki (2020) 27:13 https://doi.org/10.1186/s40709-020-00124-3 Journal of Biological Research-Thessaloniki RESEARCH Open Access Evaluating the efect of TLR4-overexpressing on the transcriptome profle in ovine peripheral blood mononuclear cells Xiaofei Guo1†, Jinlong Zhang1,2†, Yao Li2, Jing Yang1, Yihai Li1, Chunxiao Dong1, Guoshi Liu2, Zhengxing Lian2 and Xiaosheng Zhang1* Abstract Background: Toll-like receptor 4 (TLR4) plays an important role in the elimination of Gram-negative bacteria infec- tions and the initiation of antiinfammatory response. Using the technology of pronuclear microinjection, genetically modifed (GM) sheep with TLR4 overexpression were generated. Previous studies have shown that these GM sheep exhibited a higher infammatory response to Gram-negative bacteria infection than wild type (WT) sheep. In order to evaluate the gene expression of GM sheep and study the co-expressed and downstream genes for TLR4, peripheral blood mononuclear cells (PBMC) from TLR4-overexpressing (Tg) and wild type (WT) sheep were selected to discover the transcriptomic diferences using RNA-Seq. Result: An average of 18,754 and 19,530 known genes were identifed in the Tg and WT libraries, respectively. A total of 338 known genes and 85 novel transcripts were found to be diferentially expressed in the two libraries (p < 0.01). A diferentially expressed genes (DEGs) enrichment analysis showed that the GO terms of infammatory response, cell recognition, etc. were signifcantly (FDR < 0.05) enriched. Furthermore, the above DEGs were signifcantly (FDR < 0.05) enriched in the sole KEGG pathway of the Phagosome. Real-time PCR showed the OLR1, TLR4 and CD14 genes to be diferentially expressed in the two groups, which validated the DEGs data.
    [Show full text]
  • Modulation of Cell-Mediated Immunity by HIV-1 Infection of Macrophages
    Modulation of cell-mediated immunity by HIV-1 infection of macrophages Lucy Caitríona Kiernan Bell Division of Infection and Immunity University College London PhD Supervisor: Dr Mahdad Noursadeghi A thesis submitted for the degree of Doctor of Philosophy University College London August 2014 Declaration I, Lucy Caitríona Kiernan Bell, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 2 Abstract Cell-mediated immunity (CMI) is central to the host response to intracellular pathogens such as Mycobacterium tuberculosis (Mtb). The function of CMI can be modulated by human immunodeficiency virus (HIV)-1 via its pleiotropic effects on the immune response, including modulation of macrophages, which are parasitized by both HIV-1 and Mtb. HIV-1 infection is associated with increased risk of tuberculosis (TB), and so in this thesis I sought to explore the host/pathogen interactions through which HIV-1 dysregulates CMI, and thus changes the natural history of TB. Using an in vitro model of human monocyte-derived macrophages (MDMs), I characterise a phenotype wherein HIV-1 specifically attenuates production of the immunoregulatory cytokine interleukin (IL)-10 in response to Mtb and other innate immune stimuli. I show that this phenotype requires HIV-1 integration and gene expression, and may result from a function of the HIV-1 accessory proteins. I identify that the phosphoinositide 3-kinase (PI3K) pathway specifically regulates IL-10 production in human MDMs, and thus may be a target for HIV-1 to mediate IL-10 attenuation.
    [Show full text]
  • Critical Role of Oxidized LDL Receptor-1 in Intravascular
    www.nature.com/scientificreports OPEN Critical role of oxidized LDL receptor‑1 in intravascular thrombosis in a severe infuenza mouse model Marumi Ohno1, Akemi Kakino2, Toshiki Sekiya1, Naoki Nomura1, Masashi Shingai1, Tatsuya Sawamura2 & Hiroshi Kida1* Although coagulation abnormalities, including microvascular thrombosis, are thought to contribute to tissue injury and single‑ or multiple‑organ dysfunction in severe infuenza, the detailed mechanisms have yet been clarifed. This study evaluated infuenza‑associated abnormal blood coagulation utilizing a severe infuenza mouse model. After infecting C57BL/6 male mice with intranasal applications of 500 plaque‑forming units of infuenza virus A/Puerto Rico/8/34 (H1N1; PR8), an elevated serum level of prothrombin fragment 1 + 2, an indicator for activated thrombin generation, was observed. Also, an increased gene expression of oxidized low‑density lipoprotein (LDL) receptor‑1 (Olr1), a key molecule in endothelial dysfunction in the progression of atherosclerosis, was detected in the aorta of infected mice. Body weight decrease, serum levels of cytokines and chemokines, viral load, and infammation in the lungs of infected animals were similar between wild‑type and Olr1 knockout (KO) mice. In contrast, the elevation of prothrombin fragment 1 + 2 levels in the sera and intravascular thrombosis in the lungs by PR8 virus infection were not induced in KO mice. Collectively, the results indicated that OLR1 is a critical host factor in intravascular thrombosis as a pathogeny of severe infuenza. Thus, OLR1 is a promising novel therapeutic target for thrombosis during severe infuenza. Infuenza is a respiratory disease and remains a major health concern, causing approximately half a million deaths per year globally1.
    [Show full text]
  • Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies
    viruses Review Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies Laura A. Novotny 1 , John Grayson Evans 1, Lishan Su 2, Haitao Guo 3 and Eric G. Meissner 1,4,* 1 Division of Infectious Diseases, Medical University of South Carolina, Charleston, SC 29525, USA; [email protected] (L.A.N.); [email protected] (J.G.E.) 2 Division of Virology, Pathogenesis, and Cancer, Institute of Human Virology, Departments of Pharmacology, Microbiology, and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA; [email protected] 3 Department of Microbiology and Molecular Genetics, Cancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; [email protected] 4 Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA * Correspondence: [email protected]; Tel.: +1-843-792-4541 Abstract: Hepatitis B virus (HBV) chronically infects over 250 million people worldwide and causes nearly 1 million deaths per year due to cirrhosis and liver cancer. Approved treatments for chronic infection include injectable type-I interferons and nucleos(t)ide reverse transcriptase inhibitors. A small minority of patients achieve seroclearance after treatment with type-I interferons, defined as sustained absence of detectable HBV DNA and surface antigen (HBsAg) antigenemia. However, type-I interferons cause significant side effects, are costly, must be administered for months, and most patients have viral rebound or non-response. Nucleos(t)ide reverse transcriptase inhibitors reduce HBV viral load and improve liver-related outcomes, but do not lower HBsAg levels or impart Citation: Novotny, L.A.; Evans, J.G.; seroclearance.
    [Show full text]
  • TDP43 Exacerbates Atherosclerosis Progression by Promoting Inflammation and Lipid Uptake of Macrophages
    fcell-09-687169 July 2, 2021 Time: 12:55 # 1 ORIGINAL RESEARCH published: 05 July 2021 doi: 10.3389/fcell.2021.687169 TDP43 Exacerbates Atherosclerosis Progression by Promoting Inflammation and Lipid Uptake of Macrophages Ning Huangfu, Yong Wang, Zhenyu Xu, Wenyuan Zheng, Chunlan Tao, Zhenwei Li, Yewen Hu and Xiaomin Chen* Department of Cardiology, Ningbo First Hospital, Ningbo, China Objective: Atherosclerosis (AS), characterized by cholesterol overloaded-macrophages accumulation and plaque formation in blood vessels, is the major cause of cardiovascular disease. Transactive response DNA-binding protein∼43 kDa (TDP43) has recently been identified as an independent driver of neurodegenerative diseases Edited by: through triggering inflammatory response. This study investigated whether TDP43 is Yuxain Shen, involved in AS development, especially in macrophages-mediated-foam cell formation Anhui Medical University, China and inflammatory responses. Reviewed by: Juntang Shao, Methods: Transactive response DNA-binding protein∼43 kDa expressions in Anhui Medical University, China Heiko Lemcke, oxidized low-density lipoprotein (oxLDL)-treated macrophages and peripheral blood University Medical Center Rostock, mononuclear cells (PBMCs) from patients with coronary artery disease (CAD) were Germany detected by real time-polymerase chain reaction (RT-PCR), Western blot, and *Correspondence: immunofluorescence. Gene gain or loss of function was used to investigate the effects Xiaomin Chen [email protected] of TDP43 on macrophages-mediated lipid untake and inflammation with ELISA, protein immunoprecipitation, RT-PCR, Western blot, and immunofluorescence. Macrophage Specialty section: TDP43 specific knockout mice with ApoE−=− background were fed with western This article was submitted to Signaling, diet for 12 weeks to establish AS model, and used to explore the role of TDP43 a section of the journal on AS progression.
    [Show full text]